OR-USB-IF
USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced the launch of the USB-IF Conformity to IEC 62680 (USB) Specifications Program. This new initiative is designed to assist Original Equipment Manufacturers (OEMs)/Original Device Manufacturers (ODMs) in conforming to the basic requirements of the European Union (EU) Common Charger Directive, which mandates the use of standardized charging technology across a wide range of portable battery-powered devices in the EU.
In response to the EU's 2022 approval of the common charger directive—which will take effect on January 1, 2025, for portable battery-powered devices and in 2026 for laptops—the USB-IF Conformity to IEC 62680 (USB) Specifications Program specifically addresses key aspects of the directive. These include portable battery-powered devices, USB Type-C® receptacles, USB Type-C cables and connectors, external power supplies (EPS), and the USB Power Delivery (USB PD) protocol for devices advertising more than 15 Watts.
“The USB-IF has enjoyed a longstanding relationship with IEC. We contributed the core USB specifications to IEC which, once adopted, became the IEC 62680 series of USB specifications,” said USB-IF President and Chief Operating Officer Jeff Ravencraft. “The EU mandate covers only a portion of the entire USB specifications. As the industry group responsible for developing and overseeing all aspects of the USB specifications and testing, the USB-IF's new program is designed to assist OEMs/ODMs in demonstrating conformity with the EU’s requirements of the common charger directive.”
The USB-IF Conformity to IEC 62680 (USB) Specifications Program creates a simple, cost-effective process for OEMs/ODMs to demonstrate conformity to the EU Common Charger Directive. Using the USB-IF program, OEMs/ODMs can have their USB Type-C products formally tested by USB-IF authorized independent test labs (ITLs). Upon successful completion of testing, OEMs/ODMs will receive documentation to demonstrate to the EU that their products conform to the IEC 62680 (USB) specifications. This streamlined process allows for a quick testing turnaround, ensuring that manufacturers can meet regulatory deadlines:
- OEMs will continue to register their products and submit test results through ITLs, following USB-IF’s already established process.
- A minimum set of required tests has been defined by the USB-IF to demonstrate baseline conformity.
- The USB-IF will review all test result submissions and provide official approval.
- A Vendor ID (VID) is required, and USB-IF will be utilizing a Test ID (TID) as a tracker reference.
"The USB-IF Conformity to IEC 62680 (USB) Specifications Program has been crafted to ensure that all submitted products undergo evaluation, focusing on the critical elements we believe are necessary for conforming with the EU mandate,” said USB-IF Chief Technology Officer and Chairman of the Board Abdul Ismail. “Our testing levels are designed to offer a precise and reliable assessment, enabling OEMs/ODMs to confidently show to the EU that their products conform to the regulatory obligations."
While the USB-IF Conformity to IEC 62680 (USB) Specifications Program provides a vital service to OEMs/ODMs by offering a formal method to demonstrate conformity to EU mandates, it is important to distinguish this from the more extensive USB-IF Compliance Program. The USB-IF Compliance Program offers in-depth testing that not only establishes conformity with the IEC 62680 specifications but also fully verifies a product's adherence to the comprehensive USB-IF specifications for data performance, reliability and interoperability. Additionally, fully certified products qualify to be able to use the Certified USB Logo, which consumers recognize and trust to provide what they have come to expect from USB products.
“While this program is not a full certification of USB technologies, it provides a formalized pathway for OEMs/ODMs to test their products quickly,” said Ravencraft. “We are confident this new program will help the industry achieve conformity so they can continue to sell their products in the EU marketplace."
An online public listing of OEMs/ODMs products that have passed the "USB-IF Conformity to IEC 62680 (USB) Specifications Program" is located on the USB-IF product search page at www.usb.org. This platform also differentiates between products that are fully USB-IF certified and those that have met only the conformity requirements.
About USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827576634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom